000538 云南白药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入10,841,2380.62%40,033,30139,111,29236,488,37336,373,919
减:营业总成本8,751,172-2.60%35,206,79735,082,75032,087,16831,739,818
    其中:营业成本7,420,335-1.65%28,864,76628,744,51826,883,48526,498,435
               财务费用(9,204)-86.31%(155,555)(259,244)(342,878)(258,281)
               资产减值损失(23,108)-678.05%(91,231)(58,128)(664,339)(143,220)
公允价值变动收益40,965-309.82%136,837123,566(619,903)(1,929,217)
投资收益222,556-8.87%776,937779,011868,1981,044,401
    其中:对联营企业和合营企业的投资收益233,248-12.43%774,280628,532732,233(21,100)
营业利润2,255,30517.59%5,711,6224,830,5063,371,2793,485,169
利润总额2,255,98117.52%5,684,7204,818,0123,377,0023,481,646
减:所得税费用328,47048.87%917,647695,451536,593683,986
净利润1,927,51113.45%4,767,0724,122,5612,840,4102,797,661
减:非控股权益(7,128)147.08%17,65728,779(160,716)(7,256)
股东净利润1,934,64013.67%4,749,4154,093,7823,001,1262,804,917

市场价值指针
每股收益 (元) *1.08013.68%2.6602.2901.9002.210
每股派息 (元) *----2.3982.0771.5201.600
每股净资产 (元) *22.849-1.26%21.76422.19421.42829.800
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容